Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic): 2009-2025

Historic EPS (Basic) for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $0.04.

  • Gyre Therapeutics' EPS (Basic) rose 300.00% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 105.26%. This contributed to the annual value of $0.14 for FY2024, which is 109.93% up from last year.
  • As of Q3 2025, Gyre Therapeutics' EPS (Basic) stood at $0.04, which was up 748.49% from $0.00 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' EPS (Basic) peaked at $1.64 during Q2 2022, and registered a low of -$1.54 during Q4 2023.
  • In the last 3 years, Gyre Therapeutics' EPS (Basic) had a median value of $0.03 in 2025 and averaged -$0.11.
  • As far as peak fluctuations go, Gyre Therapeutics' EPS (Basic) crashed by 182.14% in 2021, and later skyrocketed by 356.25% in 2022.
  • Gyre Therapeutics' EPS (Basic) (Quarterly) stood at -$0.64 in 2021, then tumbled by 100.00% to -$1.28 in 2022, then dropped by 20.31% to -$1.54 in 2023, then soared by 99.93% to -$0.00 in 2024, then spiked by 300.00% to $0.04 in 2025.
  • Its EPS (Basic) stands at $0.04 for Q3 2025, versus $0.00 for Q2 2025 and $0.03 for Q1 2025.